These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31605245)

  • 1. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
    Hu B; Yang XB; Sang XT
    Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
    De Bruyn P; Van Gestel D; Ost P; Kruse V; Brochez L; Van Vlierberghe H; Devresse A; Del Marmol V; Le Moine A; Aspeslagh S
    Curr Opin Oncol; 2019 Mar; 31(2):54-64. PubMed ID: 30694841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 6. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 7. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
    Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
    J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of immune checkpoint inhibitors with respiratory infections: A review.
    Hamashima R; Uchino J; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Takayama K
    Cancer Treat Rev; 2020 Nov; 90():102109. PubMed ID: 33038863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
    Myers G
    Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
    Daxini A; Cronin K; Sreih AG
    Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
    Regalla DKR; Williams GR; Paluri RK
    Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.